Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib in Small Cell Lung Cancer
NCT00953459Phase 2Terminated
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Feb 2009
- Primary completion
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sunitinib in small cell lung cancer (SCLC), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Disease Control Rate at 8 weeks. Started Feb 2009; status: terminated.
02
Drugs
sunitinib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00953459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00953459.